Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Clinical trial NCT06819007 · RECRUITING
Trial details
- NCT number
- NCT06819007
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-19
- Primary completion
- 2028-11-01
- Enrollment
- 582
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.